Free biotech catalyst calendar
Each date comes with the SEC sentence it came from. Open a line to see the sentence and how its wording has changed.Each date comes with its SEC sentence.
260 programs as of
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
These records could not be loaded. Open a numbered page to read the original quotations and SEC links.
Dates the companies stated
- INOInovio Pharmaceuticals · INO-3107PDUFA target date (company stated) Quote matches the filingSEC ↗
0 days left
(PDUFA) target date for October 30, 2026.Details
INOVIO PHARMACEUTICALS, INC. (INO) · INO-3107
Stage: PDUFASEC filing · “PDUFA) target date”
Public float (as of ): $74M (SEC filing) · Under $500M
PDUFA target date (company stated):
In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act (PDUFA) target date for October 30, 2026.
Earlier SEC statements (2)
- · “In December 2025, the FDA accepted for review the company’s BLA for INO-3107 under the accelerated approval program and set a target PDUFA date for October 30, 2026.” · SEC filing
- · “In December 2025, the FDA accepted our BLA for INO-3107 for review under the accelerated approval program as a potential treatment for adults with RRP and set the Prescription Drug User Fee Act (PDUFA) target date for October 30, 2026.” · SEC filing
- AGIOAgios Pharmaceuticals · mitapivatPDUFA target date (company stated) Quote matches the filingSEC ↗
2 days left
approval pathway, is November 1, 2026.Details
AGIOS PHARMACEUTICALS, INC. (AGIO) · mitapivat
Stage: PDUFASEC filing · “PDUFA) goal date”
Public float (as of ): $1.9B (SEC filing) · $500M–$2B
PDUFA target date (company stated):
The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA’s accelerated approval pathway, is November 1, 2026.
- NRXPNRX Pharmaceuticals · KETAFREE (preservative-free ketamine) · not stated in the cited filingGDUFA goal date (company stated) Quote matches the filingSEC ↗
11 days left
the GDUFA goal date to November 10, 2026, citing that the reclassified amendment will notDetails
NRX Pharmaceuticals, Inc. (NRXP) · KETAFREE (preservative-free ketamine) · not stated in the cited filing
Stage: Not stated
Public float: Unknown (no public float found in SEC filings)
GDUFA goal date (company stated):
The acknowledgement letter revised the GDUFA goal date to November 10, 2026, citing that the reclassified amendment will not require a substantial expenditure of FDA resources.
founder confirmed 2026-10-30 · AI quote review: machine_extracted_quote_verified
Earlier SEC statements (1)
- · “The KETAFREE™ ANDA was refiled in September 2025, and the Company received a letter in November 2025 with a notice that FDA had received the file and assigning a summer 2026 decision date under the Generic Drug User Fee Act (GDUFA).” · SEC filing
- ICCCImmuCell · Unaudited financial results for the quarter and nine months ended September 30, 2026Financial results Quote matches the filingSEC ↗
14 days left
conference call on Friday, November 13, 2026, at 9:00 AM ET to discuss the unaudited financialDetails
IMMUCELL CORP /DE/ (ICCC) · Unaudited financial results for the quarter and nine months ended September 30, 2026
Stage: Not stated
Public float (as of ): $50M (SEC filing) · Under $500M
Date the company stated:
The Company is planning to host a conference call on Friday, November 13, 2026, at 9:00 AM ET to discuss the unaudited financial results for the quarter and nine months ended September 30, 2026.
15 days left
sNDA with a PDUFA date of November 14, 2026.Details
CYTOKINETICS INC (CYTK) · aficamten
Stage: PDUFASEC filing · “PDUFA date”
Public float (as of ): $2.5B (SEC filing) · Over $2B
PDUFA target date (company stated):
The FDA assigned a standard review classification to the sNDA with a PDUFA date of November 14, 2026.
- NTHINeOnc Technologies Holdings · NEO212FDA meeting Meeting date, not a results announcement Quote matches the filingSEC ↗
18 days left
and Drug Administration on November 17, 2026, for an in-person End-of-Phase 1 Type B meetingDetails
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) · NEO212
Stage: Phase 1SEC filing · “Phase 1”
Public float (as of ): $67M (SEC filing) · Under $500M
Date the company stated:
On September 28, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that it is scheduled to meet with the U.S. Food and Drug Administration on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212.
23 days left
target action date to November 22, 2026.Details
Savara Inc (SVRA) · molgramostim
Stage: PDUFASEC filing · “PDUFA") target action date”
Public float (as of ): $544M (SEC filing) · $500M–$2B
PDUFA target date (company stated):
Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.
- SNYSanofi · venglustat · type 3 Gaucher disease (GD3)FDA goal date (company stated) Quote matches the filingSEC ↗
26 days left
for the FDA decision is November 25, 2026.Details
Sanofi (SNY) · venglustat · type 3 Gaucher disease (GD3)
Stage: PDUFASEC filing · “target action date”
Public float: Unknown (no public float found in SEC filings)
FDA goal date (company stated):
The target action date for the FDA decision is November 25, 2026.
founder confirmed 2026-10-30 · AI quote review: machine_extracted_quote_verified
Earlier SEC statements (1)
- · “The target action date for the FDA decision is November 25, 2026.” · SEC filing
- PYPDPolyPid · D-PLEX100 · Prevention of surgical site infections in patients undergoing abdominal colorectal surgeryPDUFA target date (company stated) Quote matches the filingSEC ↗
29 days left
with a PDUFA goal date of November 28, 2026, including potential label expansion beyondDetails
PolyPid Ltd. (PYPD) · D-PLEX100 · Prevention of surgical site infections in patients undergoing abdominal colorectal surgery
Stage: PDUFASEC filing · “PDUFA goal date”
Public float: Unknown (no public float found in SEC filings)
PDUFA target date (company stated):
PolyPid’s management will also review the Company’s plans to maximize the value of D-PLEX₁₀₀, for which a New Drug Application (“NDA”) is under FDA Priority Review with a PDUFA goal date of November 28, 2026, including potential label expansion beyond colorectal surgery and potential geographic expansion.
founder confirmed 2026-10-30 · AI quote review: machine_extracted_quote_verified
Earlier SEC statements (1)
- · “The Company anticipates a potential FDA decision in the first quarter of 2027 under the Prescription Drug User Fee Act (“PDUFA”) review timeline.” · SEC filing
- COGTCogent Biosciences · bezuclastinib and sunitinib · GIST after prior imatinibPDUFA target date (company stated) Quote matches the filingSEC ↗
31 days left
PDUFA target action date of November 30, 2026Details
Cogent Biosciences, Inc. (COGT) · bezuclastinib and sunitinib · GIST after prior imatinib
Stage: PDUFASEC filing · “PDUFA target action date”
Public float (as of ): $772M (SEC filing) · $500M–$2B
PDUFA target date (company stated):
PDUFA target action date of November 30, 2026
Earlier SEC statements (1)
- · “PDUFA date of November 30, 2026” · SEC filing
- VRTXVertex Pharmaceuticals · povetacicept · IgA nephropathy in adultsPDUFA target date (company stated) Quote matches the filingSEC ↗
31 days left
PDUFA target action date of November 30, 2026Details
VERTEX PHARMACEUTICALS INC / MA (VRTX) · povetacicept · IgA nephropathy in adults
Stage: PDUFASEC filing · “PDUFA target action date”
Public float (as of ): $113.4B (SEC filing) · Over $2B
PDUFA target date (company stated):
PDUFA target action date of November 30, 2026
Earlier SEC statements (1)
- · “PDUFA target action date of November 30, 2026” · SEC filing
- EXELExelixis · zanzalintinib and atezolizumab · previously treated metastatic colorectal cancerPDUFA target date (company stated) Quote matches the filingSEC ↗
34 days left
target action date of December 3, 2026Details
EXELIXIS, INC. (EXEL) · zanzalintinib and atezolizumab · previously treated metastatic colorectal cancer
Stage: PDUFASEC filing · “PDUFA) target action date”
Public float (as of ): $9.4B (SEC filing) · Over $2B
PDUFA target date (company stated):
Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026
Earlier SEC statements (6)
- · “Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026” · SEC filing
- · “Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026” · SEC filing
- · “PDUFA target action date of December 3, 2026” · SEC filing
- · “target action date of December 3, 2026” · SEC filing
- · “Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026” · SEC filing
- · “Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026” · SEC filing
- ANABAnaptysBio · imsidolimab · generalized pustular psoriasisPDUFA target date (company stated) Quote matches the filingSEC ↗
43 days left
target action date of December 12, 2026Details
ANAPTYSBIO, INC (ANAB) · imsidolimab · generalized pustular psoriasis
Stage: PDUFASEC filing · “target action date”
Public float (as of ): $432M (SEC filing) · Under $500M
PDUFA target date (company stated):
target action date of December 12, 2026
Earlier SEC statements (3)
- · “target action date (PDUFA) of Dec. 12, 2026” · SEC filing
- · “target action date of December 12, 2026” · SEC filing
- · “target action date of Dec. 12, 2026” · SEC filing
- CORTCorcept Therapeutics · relacorilant · Cushing’s syndromePDUFA target date (company stated) Quote matches the filingSEC ↗
48 days left
Fee Act (PDUFA) date of December 17, 2026Details
CORCEPT THERAPEUTICS INC (CORT) · relacorilant · Cushing’s syndrome
Stage: PDUFASEC filing · “PDUFA) date”
Public float: Unknown (no public float found in SEC filings)
PDUFA target date (company stated):
Relacorilant for patients with Cushing’s syndrome – New Drug Application for relacorilant resubmitted with a Prescription Drug User Fee Act (PDUFA) date of December 17, 2026
founder confirmed 2026-10-30 · AI quote review: machine_extracted_quote_verified
Earlier SEC statements (1)
- · “Corcept expects the resubmission to receive a six-month review.” · SEC filing
- MLYSMineralys Therapeutics · lorundrostatPDUFA target date (company stated) Quote matches the filingSEC ↗
53 days left
Act (PDUFA) target date of December 22, 2026 for lorundrostat.Details
Mineralys Therapeutics, Inc. (MLYS) · lorundrostat
Stage: PDUFASEC filing · “PDUFA) target date”
Public float (as of ): $676M (SEC filing) · $500M–$2B
PDUFA target date (company stated):
The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat.
Earlier SEC statements (6)
- · “The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat.” · SEC filing
- · “The FDA accepted the NDA submission and provided the Company with a Prescription Drug User Fee Act target date of December 22, 2026 for lorundrostat.” · SEC filing
- · “Food and Drug Administration (FDA) accepted the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs and assigned a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.” · SEC filing
- · “The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.” · SEC filing
- · “The FDA accepted the NDA submission and provided us with a PDUFA target action date of December 22, 2026.” · SEC filing
- · “The FDA accepted the NDA submission and provided the Company with a Prescription Drug User Fee Act target action date of December 22, 2026.” · SEC filing
- GILDGilead Sciences · anito-cel · relapsed or refractory multiple myeloma after at least three prior therapiesPDUFA target date (company stated) Quote matches the filingSEC ↗
54 days left
PDUFA target action date of December 23, 2026Details
GILEAD SCIENCES, INC. (GILD) · anito-cel · relapsed or refractory multiple myeloma after at least three prior therapies
Stage: PDUFASEC filing · “PDUFA target action date”
Public float (as of ): $103.2B (SEC filing) · Over $2B
PDUFA target date (company stated):
PDUFA target action date of December 23, 2026
Earlier SEC statements (3)
- · “PDUFA target action date of December 23, 2026” · SEC filing
- · “PDUFA target action date of December 23, 2026” · SEC filing
- · “Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026” · SEC filing
- PRAXPraxis Precision Medicines · relutrigine · SCN2A and SCN8A developmental and epileptic encephalopathiesPDUFA target date (company stated) Quote matches the filingSEC ↗
58 days left
PDUFA target action date of December 27, 2026Details
Praxis Precision Medicines, Inc. (PRAX) · relutrigine · SCN2A and SCN8A developmental and epileptic encephalopathies
Stage: PDUFASEC filing · “PDUFA target action date”
Public float (as of ): $883M (SEC filing) · $500M–$2B
PDUFA target date (company stated):
PDUFA target action date of December 27, 2026
Earlier SEC statements (7)
- · “PDUFA action date of September 27, 2026” · SEC filing
- · “PDUFA action date of December 27, 2026” · SEC filing
- · “PDUFA date of December 27, 2026” · SEC filing
- · “PDUFA target action date from September 27, 2026” · SEC filing
- · “PDUFA target action date of September 27, 2026” · SEC filing
- · “PDUFA action date of September 27, 2026” · SEC filing
- · “target action date under the Prescription Drug User Fee Act of September 27, 2026” · SEC filing
- VTRSViatris · MR-107A-02 (fast-acting meloxicam) · moderate-to-severe acute painPDUFA target date (company stated) Quote matches the filingSEC ↗
58 days left
a PDUFA goal date of December 27, 2026.Details
Viatris Inc (VTRS) · MR-107A-02 (fast-acting meloxicam) · moderate-to-severe acute pain
Stage: PDUFASEC filing · “PDUFA goal date”
Public float: Unknown (no public float found in SEC filings)
PDUFA target date (company stated):
The FDA has assigned a PDUFA goal date of December 27, 2026.
founder confirmed 2026-10-30 · AI quote review: machine_extracted_quote_verified
- COGTCogent Biosciences · bezuclastinib · nonadvanced systemic mastocytosisPDUFA target date (company stated) Quote matches the filingSEC ↗
61 days left
target action date of December 30, 2026Details
Cogent Biosciences, Inc. (COGT) · bezuclastinib · nonadvanced systemic mastocytosis
Stage: PDUFASEC filing · “PDUFA") target action date”
Public float (as of ): $772M (SEC filing) · $500M–$2B
PDUFA target date (company stated):
Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026
Earlier SEC statements (3)
- · “PDUFA date of December 30, 2026” · SEC filing
- · “Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026” · SEC filing
- · “Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2026” · SEC filing
- NUVBNuvation Bio · taletrectinib / IBTROZIPDUFA target date (company stated) Quote matches the filingSEC ↗
66 days left
a target action date of January 4, 2027.Details
Nuvation Bio Inc. (NUVB) · taletrectinib / IBTROZI
Stage: PDUFASEC filing · “target action date”
Public float (as of ): $496M (SEC filing) · Under $500M
PDUFA target date (company stated):
supplemental New Drug Application (sNDA) for IBTROZI with updated efficacy data in TKI-naïve and TKI-pretreated advanced ROS1+ NSCLC, with a target action date of January 4, 2027.
ClinicalTrials.gov NCT04395677 · NCT stated in SEC filing
ClinicalTrials.gov NCT04919811 · NCT stated in SEC filing
- DYNDyne Therapeutics · zeleciment rostudirsen (DYNE-251) · Duchenne muscular dystrophy amenable to exon 51 skippingPDUFA target date (company stated) Quote matches the filingSEC ↗
83 days left
target action date set for January 21, 2027Details
Dyne Therapeutics, Inc. (DYN) · zeleciment rostudirsen (DYNE-251) · Duchenne muscular dystrophy amenable to exon 51 skipping
Stage: PDUFASEC filing · “PDUFA target action date”
Public float (as of ): $948M (SEC filing) · $500M–$2B
PDUFA target date (company stated):
PDUFA target action date set for January 21, 2027
Earlier SEC statements (3)
- · “Prescription Drug User Fee Act (PDUFA) target action date set for January 21, 2027” · SEC filing
- · “Prescription Drug User Fee Act, or PDUFA, target action date of January 21, 2027” · SEC filing
- · “Prescription Drug User Fee Act target action date of January 21, 2027” · SEC filing
- INSMInsmed · ARIKAYCE (amikacin liposome inhalation suspension) · Mycobacterium avium complex lung disease, as part of a combination antibacterial drug regimenFDA goal date (company stated) Quote matches the filingSEC ↗
90 days left
a target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA).Details
INSMED Inc (INSM) · ARIKAYCE (amikacin liposome inhalation suspension) · Mycobacterium avium complex lung disease, as part of a combination antibacterial drug regimen
Stage: PDUFASEC filing · “target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA”
Public float: Unknown (no public float found in SEC filings)
FDA goal date (company stated):
In September 2026, the U.S. Food and Drug Administration (FDA) accepted Insmed’s Supplemental New Drug Application (sNDA) for review of ARIKAYCE for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. The FDA granted Priority Review to the sNDA and set a target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA).
founder confirmed 2026-10-30 · AI quote review: machine_extracted_quote_verified
- PRAXPraxis Precision Medicines · ulixacaltamide · essential tremorPDUFA target date (company stated) Quote matches the filingSEC ↗
91 days left
User Fee Act, or PDUFA, of January 29, 2027Details
Praxis Precision Medicines, Inc. (PRAX) · ulixacaltamide · essential tremor
Stage: PDUFASEC filing · “target action date under the Prescription Drug User Fee Act, or PDUFA”
Public float (as of ): $883M (SEC filing) · $500M–$2B
PDUFA target date (company stated):
target action date under the Prescription Drug User Fee Act, or PDUFA, of January 29, 2027
Earlier SEC statements (5)
- · “PDUFA date of January 29, 2027” · SEC filing
- · “target action date under the Prescription Drug User Fee Act (PDUFA) of January 29, 2027” · SEC filing
- · “PDUFA target action date of January 29, 2027” · SEC filing
- · “target action date under the Prescription Drug User Fee Act, or PDUFA, of January 29, 2027” · SEC filing
- · “target action date under the Prescription Drug User Fee Act of January 29, 2027” · SEC filing
- PHARPharming Group · Joenja (leniolisib), lower-dose formulation · Activated phosphoinositide 3-kinase delta syndrome (APDS), pediatric patients aged 4–11 years weighing 13–27 kgPDUFA target date (company stated) Quote matches the filingSEC ↗
92 days left
target action date of January 30, 2027.Details
Pharming Group N.V. (PHAR) · Joenja (leniolisib), lower-dose formulation · Activated phosphoinositide 3-kinase delta syndrome (APDS), pediatric patients aged 4–11 years weighing 13–27 kg
Stage: PDUFASEC filing · “PDUFA) target action date”
Public float: Unknown (no public float found in SEC filings)
PDUFA target date (company stated):
On September 28, 2026, we announced that the FDA had accepted this sNDA and granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027.
founder confirmed 2026-10-30 · AI quote review: machine_extracted_quote_verified
Earlier SEC statements (1)
- · “The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027.” · SEC filing
- GILDGilead Sciences · lenacapavir oral 300-mg · HIV pre-exposure prophylaxisPDUFA target date (company stated) Quote matches the filingSEC ↗
95 days left
target action date of February 2, 2027Details
GILEAD SCIENCES, INC. (GILD) · lenacapavir oral 300-mg · HIV pre-exposure prophylaxis
Stage: PDUFASEC filing · “PDUFA”) target action date”
Public float (as of ): $103.2B (SEC filing) · Over $2B
PDUFA target date (company stated):
Prescription Drug User Fee Act (“PDUFA”) target action date of February 2, 2027
Earlier SEC statements (1)
- · “Prescription Drug User Fee Act target action date of February 2, 2027” · SEC filing
- ARQTArcutis Biotherapeutics · roflumilast cream 0.05%PDUFA target date (company stated) Quote matches the filingSEC ↗
116 days left
set target action date of February 23, 2027Details
Arcutis Biotherapeutics, Inc. (ARQT) · roflumilast cream 0.05%
Stage: PDUFASEC filing · “target action date”
Public float (as of ): $1.5B (SEC filing) · $500M–$2B
PDUFA target date (company stated):
FDA accepted sNDA for ZORYVE cream 0.05% to expand indication to include infants with mild to moderate atopic dermatitis aged 3 to 24 months and set target action date of February 23, 2027
- CGEMCullinan Therapeutics · zipalertinibPDUFA target date (company stated) Quote matches the filingSEC ↗
120 days left
target action date of February 27, 2027.Details
Cullinan Therapeutics, Inc. (CGEM) · zipalertinib
Stage: PDUFASEC filing · “PDUFA) target action date”
Public float (as of ): $442M (SEC filing) · Under $500M
PDUFA target date (company stated):
An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.
Earlier SEC statements (4)
- · “FDA assigned a Prescription Drug User Fee Act target action date of February 27, 2027.” · SEC filing
- · “The Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027.” · SEC filing
- · “The Prescription Drug User Fee Act target action date is February 27, 2027.” · SEC filing
- · “The Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027.” · SEC filing
- BMRNBiomarin Pharmaceutical · vosoritide · children with achondroplasia; full approval applicationPDUFA target date (company stated) Quote matches the filingSEC ↗
121 days left
target action date of February 28, 2027Details
BIOMARIN PHARMACEUTICAL INC (BMRN) · vosoritide · children with achondroplasia; full approval application
Stage: PDUFASEC filing · “PDUFA) target action date”
Public float (as of ): $6.7B (SEC filing) · Over $2B
PDUFA target date (company stated):
Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027
Earlier SEC statements (1)
- · “Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027” · SEC filing
- NTLAIntellia Therapeutics · lonvoguran ziclumeran · hereditary angioedemaPDUFA target date (company stated) Quote matches the filingSEC ↗
131 days left
PDUFA target action date of March 10, 2027Details
Intellia Therapeutics, Inc. (NTLA) · lonvoguran ziclumeran · hereditary angioedema
Stage: PDUFASEC filing · “PDUFA target action date”
Public float (as of ): $869M (SEC filing) · $500M–$2B
PDUFA target date (company stated):
PDUFA target action date of March 10, 2027
Earlier SEC statements (4)
- · “Prescription Drug User Fee Act (PDUFA) date of March 10, 2027” · SEC filing
- · “Prescription Drug User Fee Act ("PDUFA") target action date of March 10, 2027” · SEC filing
- · “Prescription Drug User Fee Act (“PDUFA”) target action date of March 10, 2027” · SEC filing
- · “PDUFA target action date of March 10, 2027” · SEC filing
- ETONEton · LIBERVANT (diazepam buccal film) · seizure clusters, ages 6–11PDUFA target date (company stated) Quote matches the filingSEC ↗
150 days left
target action date of March 29, 2027.Details
ETON (ETON) · LIBERVANT (diazepam buccal film) · seizure clusters, ages 6–11
Stage: PDUFASEC filing · “PDUFA) target action date”
Public float: Unknown (no public float found in SEC filings)
PDUFA target date (company stated):
The NDA has a Prescription Drug User Fee Act (PDUFA) target action date of March 29, 2027.
November 2026: company-stated PDUFA, data and conference timing
No program matches these filters.
About this calendar
FDA dates and trial readouts as each company stated them, with SEC original links. 260 programs as of . Free, with no sign-in. No forecasts, prices or signals.
Add to Google Calendar Apple Calendar The subscription follows the filters chosen here. Calendar exports use exact company-stated dates. Period wording remains in the records. No sign-up; ORION stores nothing about subscribers.
How this calendar is made
- Entries are grouped by their retained period length: an exact date (with its count of days), then a month, quarter, half or year with no count. Calendar subscriptions include exact dates. Period headings describe the window end; each row retains the company's exact wording. A date is the target action date the company stated.
- Company size is the public float (market value of shares held by non-affiliates) on the company’s latest cover, with its reference date and SEC link. It does not decide which programs are listed.
- Stage repeats the SEC filing or ClinicalTrials.gov registration wording. Without supporting wording, it is Not stated. Mixed phases retain their exact wording beside the source link.
- Medicine research links use an NCT number stated in the SEC filing or company announcement, or a ClinicalTrials.gov match with sponsor, medicine and phase evidence. A registry match is labelled “matched by ORION (not stated in the filing)”.
- Rows link to the program or company page. For a stated date, month, quarter, half or year, the period ends on its calendar end. Ambiguous qualifiers retain their wording without inferred endpoints.
- Ambiguous periods and events without a date retain the literal wording in a separate section. No calendar date or countdown is created; these records are excluded from calendar subscriptions.
- Active windows have no resolution filing held and end on or after today (UTC). A row with resolution evidence is shown in Results disclosed. Other rows move to Window ended after the stated period ends. Earlier wording and filing links remain available.
- Event types distinguish trial data, enrollment completion, site activation and event-based analysis. Financial results and FDA meetings have their own filters. Audit status remains in the SEC wording. The type follows the SEC wording.
- Displayed items need a true public-display field and a matching SEC quote and timing proof. Machine extraction does not add a founder review.
- “Wording changed” opens the earlier sentences, each with its date and filing.
- No forecast, price, score or signal. The calendar repeats what companies wrote.
Window ended
The company-stated period has ended. These records retain their wording and filing links.
4 programs as of
No ended windows match these filters.
Timing without a stated calendar date
These SEC statements retain an ambiguous period or an event trigger. No date or countdown is assigned.
10 records as of
No records match these filters. Choose All periods to view timing without a calendar date.
Results disclosed
An SEC resolution filing is held in these records. The original schedule, quote and source remain available.
53 programs as of
No disclosed records match these filters.
All companies A–Z · Korea → US Licensing Ledger